The Worldwide Pharmacovigilance & Drug Safety Software Industry is Expected to Reach $940 Million by 2027 – ResearchAndMarkets.com
November 21, 2022DUBLIN–(BUSINESS WIRE)–The “Pharmacovigilance & Drug Safety Software Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.
The Global Pharmacovigilance & Drug Safety Software Market is projected to reach USD 940.58 million by 2027 from USD 426.74 million in 2021, at a CAGR of 14.07% during the forecast period.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available.
In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
- The Americas Pharmacovigilance & Drug Safety Software Market size was estimated at USD 169.55 million in 2021 and expected to reach USD 189.13 million in 2022, at a CAGR of 13.37% to reach USD 360.12 million by 2027.
- The Asia-Pacific Pharmacovigilance & Drug Safety Software Market size was estimated at USD 99.09 million in 2021 and expected to reach USD 115.28 million in 2022, at a CAGR of 14.94% to reach USD 228.61 million by 2027.
- The Europe, Middle East & Africa Pharmacovigilance & Drug Safety Software Market size was estimated at USD 158.09 million in 2021 and expected to reach USD 180.55 million in 2022, at a CAGR of 14.26% to reach USD 351.84 million by 2027.
Market Segmentation & Coverage:
The report on pharmacovigilance & drug safety software identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan.
This research report categorizes the pharmacovigilance & drug safety software to forecast the revenues and analyze the trends in each of the following sub-markets:
Product:
- Adverse Event Reporting Software
- Drug Safety Audits Software
- Fully Integrated Software
- Issue Tracking Software
Clinical Trial:
- Phase I
- Phase II
- Phase III
- Phase IV
- Pre-clinical
Distribution:
- On-Cloud
- On-Premise
End User:
- Business Process Outsourcing Firms
- Contract Research Organizations
- Pharma & Biotech Companies
- Pharmacovigilance Service Providers
Region:
-
Americas
- Argentina
- Brazil
- Canada
- Mexico
-
United States
- Arkansas
- California
- Florida
- Illinois
- Kentucky
- Minnesota
- New Jersey
- New Mexico
- New York
- Ohio
- Pennsylvania
- Texas
-
Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
-
Europe, Middle East & Africa
- France
- Germany
- Italy
- Netherlands
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- United Arab Emirates
- United Kingdom
Company Usability Profiles:
- 4C Pharma Solutions
- AB Cube
- Accenture PLC
- Advera Health Analytics, Inc.
- Anju Software, Inc.
- ArisGlobal LLC
- Clinevo Technologies Private Limited
- Cognizant Technology Solutions Corporation
- Ennov
- Ergomed PLC
- Extedo GmbH
- Indegene Inc.
- IQVIA Inc.
- Oracle Corporation
- Sarjen Systems Private Limited
- Sparta Systems, Inc.
- United BioSource LLC
- Wipro Limited
For more information about this report visit https://www.researchandmarkets.com/r/hiwrly
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900